NCT07105722

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of An Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 127 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 50 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.

Conditions

• Pneumonia, Bacterial

Interventions

Type	Name	Description
BIOLOGICAL	Pn-MAPS30plus	The Pn-MAPS30plus vaccine will be administered intramuscularly.
COMBINATION_PRODUCT	PCV20	The PCV20 vaccine will be administered intramuscularly.

Timeline

• Start date: 2025-08-12
• Primary completion: 2026-06-09
• Completion: 2026-06-09
• First posted: 2025-08-06
• Last updated: 2025-12-24

Locations

4 sites across 1 country: Australia